These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 33023488)

  • 1. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
    BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
    Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW;
    Mult Scler; 2018 Apr; 24(4):535-539. PubMed ID: 28304217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS;
    Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
    Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS
    J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
    Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
    Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide in multiple sclerosis: an update.
    Miller AE
    Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Sprenger T; Kappos L; Sormani MP; Miller AE; Poole EM; Cavalier S; Wuerfel J
    Mult Scler; 2022 Oct; 28(11):1719-1728. PubMed ID: 35485424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS;
    Mult Scler; 2012 Nov; 18(11):1625-32. PubMed ID: 22723573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
    Miller AE; Olsson TP; Wolinsky JS; Comi G; Kappos L; Hu X; Xu X; Lublin AL; Truffinet P; Chavin J; Delhay JL; Benamor M; Purvis A; Freedman MS;
    Mult Scler Relat Disord; 2020 Nov; 46():102438. PubMed ID: 32911306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
    Scott LJ
    Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.